9 results about "Corneal cell" patented technology

The ophthalmic composition according to the present invention contains: (A) 0.01-0.5 w / w% of a copolymer having structural units represented by formulae (1a)-(1c), the molar ratio of the structural units being a: b: c = 100: 10-400: 2-50, and the weight-average molecular weight being 5,000-2,000,000; (B) from 0.001 w / w% to 0.02 w / w% (inclusive) of benzalkonium chloride; and / or (C) from 0.001 w / w% to 0.05 w / w% (inclusive) of chlorhexidine gluconate. According to the present invention, it is possible to provide an ophthalmic composition that protects corneal cells while exhibiting sufficient storage efficacy.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

The invention discloses a low-energy photocuring ophthalmic sealant and a preparation method and application thereof.The ophthalmic sealant is in-situ photocuring bi-crosslinking biological hydrogel, a functional complementary composite system is constructed through collaborative optimization, and the ophthalmic sealant mainly comprises methacrylated gelatin (GelMA), a cornea extracellular matrix component, glutamine transaminase and a photoinitiator. According to the invention, a double-network construction strategy combining low-energy photocuring and enzymatic crosslinking is adopted, and curing can be triggered under the extremely low optical power density not higher than 5 mW / cm, so that the clinical application bottlenecks of tissue damage caused by too high energy of a traditional photocuring material for eyes and insufficient mechanical property and stability of a single crosslinking system are overcome. The sealing agent has excellent tissue adhesion, mechanical stability and biocompatibility in a double-crosslinking hydrogel state, can realize minimally invasive sutureless repair of corneal defects, and effectively promotes functional regeneration of corneal tissues.

The invention discloses a non-invasive refraction treatment device and method, and the device comprises a hard cornea contact lens; the flexible circuit patch is connected with the rigid cornea contact lens, and the flexible circuit patch comprises an electrode structure; the generating device is used for electrifying the electrode structure in a wireless or wired manner, and an electric field is generated between the positive electrode and the negative electrode of the electrode structure and is used for generating a current path in a cornea and softening cornea tissues when the hard cornea contact lens is placed into an eye. The corneal shaping method has the following beneficial effects: 1, the whole shaping process only needs several minutes, so that the corneal shaping time is greatly shortened; and 2, the temperature change in the eyes of the wearer is detected and the discharge pulse width, voltage and discharge frequency of the pulse generation device are dynamically adjusted while programmed control and current release are carried out, so that corneal cell damage caused by temperature rise is avoided, the corneal shaping risk is reduced, and the safety is greatly improved.

The application provides a method for constructing a tissue-engineered cornea based on human amniotic epithelial stem cells and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induction and differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stromal cell induction and differentiation culture medium to obtain corneal stromal cells; 2) inoculating the human corneal epithelial cell-like cells and the corneal stromal cells obtained in step 1) on the surface and inside of a decellularized corneal stromal scaffold respectively, and co-culturing for 5 days to construct a tissue-engineered cornea. The application successfully constructs a tissue-engineered cornea by inoculating two kinds of corneal cells derived from human amniotic epithelial stem cells on a human decellularized corneal stromal at the same time for the first time. In addition, the obtained corneal cells can be inoculated on various types of biomaterials such as hydrogels, thereby providing a wider application possibility for developing various types of artificial cornea products.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The present invention relates to a corneal cell culture support comprising graphene and its uses. The graphene-containing support of the present invention is non-toxic to corneal cells, is optimized for the cell proliferation rate, adhesion rate, and survival rate of corneal cells, enhances the expression of corneal cell-specific genes, and can maintain an optimized corneal cell state through cytoskeletal remodeling and mitochondrial activation. Therefore, the corneal cell culture support has the effect of being utilized in cell therapies, implant materials in the field of regenerative medicine, and tissue engineering platforms.

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

The embodiment of the invention provides an application of a proton pump inhibitor or a derivative thereof, or a compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof in preparation of anti-xerophthalmia drugs. The proton pump inhibitor is prepared from any one or a combination of at least two of omeprazole, lansoprazole, pantoprazole, rabeprazole, reminoprazole, esomeprazole or tenatoprazole. According to the application, the proton pump inhibitor is loaded on the self-assembled nucleic acid, so that the composite material has efficient corneal cell membrane penetrating capacity, and can remarkably inhibit expression of inflammatory factors and improve the ocular surface inflammation microenvironment; in addition, the compound also has relatively good biological safety, shows an excellent treatment effect on in-vivo and in-vitro xerophthalmia models, and provides a new choice for clinical xerophthalmia treatment.